A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting 70 enrolled CStone Pharmaceuticals Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China

Timeline

Start: 2022-05-27
Primary completion: 2023-12-26
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorlatinib	Small molecule	100 mg	Oral

Indications

No indication recorded.